Preliminary Trial of SNA014 for Pancreatic Cancer
A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer
1 other identifier
interventional
12
1 country
1
Brief Summary
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for early_phase_1 pancreatic-cancer
Started Oct 2025
Shorter than P25 for early_phase_1 pancreatic-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2025
CompletedFirst Submitted
Initial submission to the registry
April 21, 2026
CompletedFirst Posted
Study publicly available on registry
May 19, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
May 19, 2026
April 1, 2026
9 months
April 21, 2026
May 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
The safety and tolerability profile of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
Occurrence of AE/SAE according to CTCAE 5.0
1 week
CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
SUVmax of tumors
1 week
CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
SUVmean of tumors
1 week
CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
Correlation of tumor uptakes and Immunohistochemistry
1 week
Study Arms (1)
Group
EXPERIMENTAL68Ga-NODAGA-SNA006
Interventions
Eligibility Criteria
You may qualify if:
- Aged between 18 and 75 years (inclusive);
- Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
- Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
- Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
- Pathology test results from within the past year;
You may not qualify if:
- Patients with other clearly diagnosed malignant tumours;
- Patients with uncontrolled severe infections, or those with other serious comorbidities;
- Patients with a life expectancy of ≤3 months;
- Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
- Patients deemed unsuitable for participation in this study by the investigator.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 21, 2026
First Posted
May 19, 2026
Study Start
October 1, 2025
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
May 19, 2026
Record last verified: 2026-04